Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 403

Similar articles for PubMed (Select 16518757)

1.

CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?

Newell ML, Patel D, Goetghebuer T, Thorne C; European Collaborative Study.

J Infect Dis. 2006 Apr 1;193(7):954-62. Epub 2006 Feb 23.

2.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A; Spanish Group of Paediatric HIV Infection.

Clin Infect Dis. 2006 Mar 15;42(6):862-9. Epub 2006 Feb 9.

3.

Height, weight, and growth in children born to mothers with HIV-1 infection in Europe.

Newell ML, Borja MC, Peckham C; European Collaborative Study.

Pediatrics. 2003 Jan;111(1):e52-60.

PMID:
12509595
4.

Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers.

Bunders M, Thorne C, Newell ML; European Collaborative Study.

AIDS. 2005 Jul 1;19(10):1071-9.

PMID:
15958839
5.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
6.

Impact on weight and height with the use of HAART in HIV-infected children.

Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA.

Pediatr Infect Dis J. 2007 Apr;26(4):334-8.

PMID:
17414398
8.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.

9.

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

Ahdieh Grant L, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, Nowicki M, Kovacs A, Cohen M, Muñoz A.

AIDS. 2001 Nov 9;15(16):2101-8.

PMID:
11684929
10.

Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.

Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, Badolato R, Giaquinto C, Lisi C, de Martino M; Italian Register for HIV Infection in Children.

AIDS. 2006 Jan 9;20(2):207-15. Erratum in: AIDS. 2006 Aug 22;20(13):1789. Baddato, Raffaele [corrected to Badolato, Raffaele].

PMID:
16511413
11.

Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya.

Nyandiko WM, Ayaya S, Nabakwe E, Tenge C, Sidle JE, Yiannoutsos CT, Musick B, Wools-Kaloustian K, Tierney WM.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):418-25.

PMID:
17099313
12.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
13.

Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children.

Abrams EJ, Wiener J, Carter R, Kuhn L, Palumbo P, Nesheim S, Lee F, Vink P, Bulterys M; Perinatal AIDS Collaborative Transmission Study (PACTS) Group.

AIDS. 2003 Apr 11;17(6):867-77.

PMID:
12660534
14.

[Responses to antiretroviral treatments in vertically HIV-1-infected children].

Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA, Muñoz-Fernández MA.

Med Clin (Barc). 2002 Nov 30;119(19):725-9. Spanish.

PMID:
12487967
15.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.

Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA.

AIDS. 2002 Feb 15;16(3):359-67.

PMID:
11834947
16.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.

AIDS. 2007 May 11;21(8):939-46.

PMID:
17457087
17.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
18.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
19.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
20.

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.

Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, Giorgi J, Muñoz A.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):168-75.

PMID:
11404539
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk